Zeta Global's Q4 2025 earnings reveal that early Athena users are delivering a notable incremental ARPU uplift compared to non-Athena cohorts, driven by enhanced workflow efficiency and higher ROI. Although exact figures are not disclosed, management highlights material spending increases and anticipates future growth as Athena adoption expands.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
Can you quantify the incremental ARPU uplift early Athena users are delivering versus non-Athena cohorts?
Analysis of Incremental ARPU Uplift from Early Athena Users versus Non-Athena Cohorts at Zeta Global
Zeta Global’s earnings disclosures reveal key insights about the incremental Average Revenue Per User (ARPU) uplift attributable to early Athena users compared to those customers not yet using Athena:
Early Athena Users Spend Materially More:
CEO David Steinberg explicitly states that early access Athena clients are "spending materially more with Athena than they were without her" and are experiencing a "game-changing workflow environment" leading to "substantially higher return on investment" than non-Athena users 12. Although exact absolute ARPU figures specific to Athena users are not disclosed, the qualitative comment highlights a meaningful incremental uplift.
Return on Ad Spend (ROAS) Improvement Underpins Uplift:
Zeta reports an existing platform-wide average ROAS of 600%. The use of Athena is said to drive "substantially higher return on investment than the existing 600% return on ad spend" 2. Higher ROAS typically translates into clients allocating more marketing dollars to Zeta’s platform, driving increased ARPU.
Overall ARPU Growth in Customer Cohorts Suggests Athena Benefit:
Current Revenue Guidance Reflects Minimal Athena Impact but Anticipates Incremental Upside:
The company guides for revenue growth excluding Athena-driven revenue as conservative, with minimal Athena contribution "right now" yet acknowledging Athena "should also be incremental upside" 67. This implies early Athena user ARPU uplift is not yet fully reflected in reported financials but is a recognized driver for future growth.
Athena as a Workflow and ROI Multiplier Driving Expansion:
Feedback from early Athena users highlights significant time savings and better ROI on segmentation, production, and analysis 8. This workflow transformation drives deeper platform adoption and higher utilization, both of which correlate to increased spending (ARPU) per user.
| Metric / Cohort | ARPU / Growth Insight | Citation(s) |
|---|---|---|
| Super-scaled customer quarterly ARPU | $1.8 million, +5% YoY (+mid-teens % normalized) | 3 |
| 5+ Year customer cohort ARPU growth | +39% YoY (fastest-growing ARPU cohort) | 4 |
| 1-3 Year cohort average ARPU | $1.1 million | 4 |
| 1st year cohort average ARPU | $709,000 | 4 |
| Multi-use case customer revenue uplift | 200%-300% increase vs single-use case customers | 5 |
| Early Athena user spending | Materially higher spend and significantly improved ROI | 182 |
| Current revenue guidance on Athena | Minimal contribution assumed; upside potential noted | 67 |
In sum, early Athena users are delivering a discernible and material incremental ARPU uplift compared to non-Athena cohorts, although the company has not yet quantified specific dollar amounts in public disclosures as of Q4 2025. The trajectory of ARPU among key cohorts and customer behavioral patterns affirm Athena’s role as a powerful revenue accelerator and value enhancer for Zeta Global.
References:
18234567
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
Zeta Global reported a strong Q1 2026 with revenue exceeding the guidance midpoint by $26 million, affirming its positive financial trajectory.
Sources used
Research questionBy how much did Zeta beat the midpoint of its Q1 revenue guidance and what point increase did management report?
Answer outline
Zeta Global's Q4 2025 earnings reveal significant ARPU growth driven by customer expansion, multi-use-case adoption, and effective strategic sales execution. The company’s advanced platform and AI capabilities further support this expansion.
Sources used
Research questionWhat drove the increase in ARPU for Zeta Global?
Answer outline
Marvell attributes near-term data center margin pressure to the expanding mix of custom silicon, with management emphasizing that revenue levels and product mix drive gross margins each quarter. While the Q3 headwind is primarily a mix effect, management expects margins to stabilize as the custom ramp accelerates in H2 and broad-based growth supports margin expansion into fiscal 2028.
Sources used
Research questionWhat did management say about Data center margin drivers from custom mix?
Answer outline
Investors should read management’s “2H acceleration” as a qualitative uptick in the second half versus the first half, supported by guidance for sequential back-half growth and a Helios ramp that becomes more impactful in Q4. The Q2 107% YoY growth establishes the first-half baseline, with Q3 and Q4 expected to exceed it through supply and product timing.
Sources used
Research questionHow should investors interpret management’s view that data center AI growth will “accelerate” in the second half versus the first half, given Q2’s 107% year-over-year growth and the Q3/Q4 guidance trajectory?
Answer outline
Western Digital outlines a dual-path outlook: LTA pricing remains contract-driven and predictable, particularly for nearline pricing, while offering upside in non-nearline contracts, and the exabyte growth trajectory remains robust at 25% plus, supported by 40TB ePMR ramp and upcoming HAMR and higher-capacity drives, with visibility extending through 2029–2031. Quarterly margins may vary due to LTA timing, but the long-term demand signal remains strong.
Sources used
Research questionWhat did management say about LTA pricing and exabyte growth outlook?
Answer outline
Pfizer's update highlights a $1.5 billion year-to-date non-COVID uplift driven by Eliquis alongside other products like NURTEC and Padcev, though the exact split isn’t quantified. Eliquis is projected to grow 20%–25% this year, while Padcev shows an initial acceleration that should moderate as la/mUC penetration matures, with upside potential from MIBC over time.
Sources used
Research questionWithin the $1.5 billion year-to-date increase in non-COVID revenue guidance, how much is due to Eliquis versus other products, and what is the updated Eliquis growth outlook? Also, with Padcev's expanded label, what is the expected growth path for that asset going forward?
Answer outline
Match Group's Q2 2026 earnings discussion centers on a consistent MAU-payer trend correlation, where payer declines run smaller than MAU declines and payer penetration rose year over year. Management notes MAU momentum drives direct revenue per MAU and payer trends over time, but warns quarterly movements can diverge due to product and monetization initiatives, while maintaining a positive long-term outlook and guidance for payer declines to ease in H2.
Sources used
Research questionWhat did management say about MAU and payer trend correlation?
Answer outline
IFF's Scent segment posted an 8% Q2 sales rise led by double-digit growth in Fragrance Ingredients and a resilient Consumer Fragrance line, even as Fine Fragrance faced Middle East volatility. The firm outlines a two-track H2: mid-single-digit growth for Fine Fragrance with a Q3 soft patch and a rebound in Q4, while Consumer Fragrance normalizes after a standout Q2, underpinned by an R&D-driven push into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is advancing on multiple fronts, led by volume-driven growth, a re-energized R&D pipeline, and stable management of regional volatility. In 2H, Fine Fragrance should soften in Q3 and rebound in Q4, while Consumer Fragrance normalizes to a low single-digit pace, with 2027 R&D investments positioned to bolster long-term competitive strength.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Management ties the Scent recovery to a significantly stronger R&D pipeline and execution, with Scent sales up 8% and EBITDA up 5% driven by volume gains and productivity. For 2H, Fine Fragrance is expected to be soft in Q3 but stronger in Q4, while Consumer Fragrance should normalize to low-single-digit growth; the 2027 plan emphasizes sustained R&D investment, perfumer-led innovation, and a shift toward higher-value natural ingredients.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is led by Fragrance Ingredients and volume gains, with Fine Fragrance expected to be softer in Q3 and rebound in Q4. The company emphasizes a rebuilt R&D pipeline and higher-value product shifts to support competitive positioning into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery driven by a strengthened R&D pipeline, improved go-to-market execution, and a strategy to lift market share across Fine and Consumer Fragrance. The company anticipates a softer Q3 but a stronger Q4 for Fine Fragrance and a normalization to low single-digit growth for Consumer Fragrance in H2, supported by an 8-9% of sales R&D investment through 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi